EMA Approval Under Exceptional Circumstances
How we worked with an approved BLA to fit EU requirements for an MAA submission, resulting in EMA approval.
You’ve developed a novel drug and obtained FDA approval. Your work is done, right? Not if you want to market your product outside the US. For many Sponsors, the logical next step is to enter the European market.
Where do you start? What data is needed and what can be repurposed from your FDA submission? How long will the process take? These are just a few of the many questions you probably have, but the good news is that ProPharma Group's team of experienced regulatory experts is here to help.
Learn how our regulatory experts helped one client obtain EMA approval under exceptional circumstances using an innovative approach to working with the available BLA to make it fit for the purpose of the MAA submission.
Related Resources
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma Group offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma Group’s Compliance and Quality team completed the...
Navigating the Generic Drug Application and Approval Process
Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...